When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be ...

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a ...

Fintel reports that on May 28, 2025, Stifel downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from Buy to Hold.

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational ...

Fintel reports that on May 27, 2025, HC Wainwright & Co. downgraded their outlook for Vigil Neuroscience (NasdaqGS:VIGL) from ...

After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi SAN-5.48%decrease; red down pointing triangle said it entered an agreement to acquire Vigil Neuroscience VIGL-0.13%decrease; red down pointing triangle for approximately $470 million ...

On Tuesday, Stifel analysts downgraded Vigil Neuroscience Inc (NASDAQ: VIGL) stock from a Buy to a Hold rating, concurrently reducing the price target from $11.00 to $8.00. This adjustment comes ...